Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Other financing activities (2022 - 2025)

Oramed Pharmaceuticals' Other financing activities history spans 4 years, with the latest figure at $3.2 million for Q4 2025.

  • For Q4 2025, Other financing activities changed N/A year-over-year to $3.2 million; the TTM value through Dec 2025 reached $6.9 million, changed N/A, while the annual FY2025 figure was $6.0 million, 49.87% up from the prior year.
  • Other financing activities reached $3.2 million in Q4 2025 per ORMP's latest filing, up from $719000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $6.7 million in Q4 2023 to a low of -$1.8 million in Q2 2023.
  • Average Other financing activities over 4 years is $1.2 million, with a median of $800000.0 recorded in 2025.
  • Peak YoY movement for Other financing activities: plummeted 128.03% in 2023, then surged 1142.28% in 2024.
  • A 4-year view of Other financing activities shows it stood at $2.9 million in 2022, then soared by 135.86% to $6.7 million in 2023, then tumbled by 95.76% to $286000.0 in 2024, then surged by 1022.38% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Other financing activities are $3.2 million (Q4 2025), $719000.0 (Q3 2025), and $800000.0 (Q2 2025).